# Shanghai Hanyu Medical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-hanyu-medical-technology-co

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.hanyumedical.com
- Total disclosed funding: $163M
- Latest round: Series D (Mar 15, 2021)
- Investors on record: 18

## About

Shanghai Hanyu Medical Technology Co., Ltd. is dedicated to advancing healthcare through innovative interventional devices for structural heart diseases, focusing on improving patient outcomes and quality of life.Founded in 2016 and headquartered in Shanghai, China, Shanghai Hanyu Medical Technology Co., Ltd. specializes in the development of medical technology aimed at treating structural heart diseases. The firm has successfully secured 11 deals, with its most recent funding round occurring on March 15, 2021. The company raised RMB 500 million in its Series D funding round, led by YF Capital and included participation from several other investment firms. There are no known changes in business operations or subsidiaries associated with the company.Shanghai Hanyu Medical Technology Co., Ltd. specializes in the research, development, production, and commercialization of interventional devices for structural heart diseases. Its flagship product, the ValveClamp® Mitral Valve Clip System, received approval from the National Medical Products Administration in September 2023, making it the first domestically approved intervention device for mitral regurgitation in China. In addition to the ValveClamp®, the company has developed the ReAces (also known as ??), a novel atrial septal defect occluder that has completed clinical enrollment and is undergoing follow-up studies. Hanyu Medical's products are in clinical use across over 60 hospitals in China and are commercially available in more than 20 countries, including Indonesia.Hanyu Medical's revenue model primarily revolves around the sale of its proprietary medical devices, including the ValveClamp® and ReAces, to hospitals and healthcare facilities. Transactions typically occur through direct sales to medical institutions, which utilize these devices in various cardiovascular procedures. The company’s focus on innovative and high-quality products fosters long-term partnerships with healthcare providers, who may purchase devices based on specific patient needs and procedural requirements.In March 2021, Shanghai Hanyu Medical Technology Co., Ltd. raised RMB 500 million through Series D funding, led by YF Capital, with funds aimed at supporting the development of additional interventional devices and expanding their market presence. The company plans to launch its new products within the next couple of years, targeting expansion into additional Asian markets and strengthening its presence in regions such as Southeast Asia and Europe by 2025.

## Funding rounds

- Series D, Mar 15, 2021, $77M — YF Capital, Jiangsu Winfast Investment Holding Group, HighLight Capital, E Fund Management Co.,Ltd, Octagon Capital Advisors, Linden Asset Group
- Series D, Aug 13, 2020, $72M — CPE Funds Management, Orient Securities Capital, HighLight Capital, Everest VC, MED-FINE Capital, Yingke Private Equity, TF Capital, Spring Fund, ALAN AMC, Hefang Kechuang
- Series B, Dec 27, 2018, $15M — Lotus Lake Capital, In Capital, Yingke Private Equity
- Series A, Apr 12, 2018 — TigerYeah Capital

## Investors

- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series A
- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series B
- In Capital — Series B
- Yingke Private Equity (https://capitalatlas.ai/funds/yingke-private-equity) — Series B, Series D
- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series D
- Orient Securities Capital — Series D
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series D
- Everest VC (https://capitalatlas.ai/funds/everest-vc) — Series D
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series D
- TF Capital — Series D
- Spring Fund (https://capitalatlas.ai/funds/spring-fund) — Series D
- ALAN AMC (https://capitalatlas.ai/funds/alan-amc) — Series D
- Hefang Kechuang — Series D
- YF Capital (https://capitalatlas.ai/funds/yf-capital) — Series D
- Jiangsu Winfast Investment Holding Group — Series D
- E Fund Management Co.,Ltd — Series D
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series D
- Linden Asset Group — Series D